AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01397461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozenoxacin 1% cream
Description: 1% cream
Study NCT04827888 — intervention group
Intervention type: PROCEDURE
Intervention: Orthopaedic surgery
Description: One of the 25 most common orthopedic surgeries reported in the database which are the following as per surgical types: spine surgery (CPT codes 63030, 63047, 22612, 22551 or 22558), trauma (CPT codes 27236, 27125, 27244, 27814, or 27792), sports medicine injuries (CPT codes 29881, 29827, 29880, 29888, 29826, 29877, 29807, or 23412), or joint arthroplasty (CPT codes 27447, 27130, 23472, 27487, 27134, 27446, or 27486).
Study NCT03632772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin 5Mg
Description: We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
Study NCT03632772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
Study NCT01131325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
Study NCT05722756 — intervention group
Intervention type: OTHER
Intervention: craniosacral therapy
Description: subtle form of applied touch, type of osteopathy
Study NCT02637999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2a
Study NCT01884896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER Tablet 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT01884896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER Tablet 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT01884896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'TOPROL-XL®' ER Tablets 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT01884896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'TOPROL-XL®' ER Tablets 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT00921791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBPM
Description: Automatic oscillometric device for home blood pressure measurement and usual care.
Study NCT00921791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBPM and Pharmaceutical care
Description: Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
Study NCT00921791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care
Description: consultations with the pharmacists
Study NCT00921791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Consultation with the physician.
Study NCT02436616 — intervention group
Intervention type: DEVICE
Intervention: microEEG
Description: microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation.
Study NCT03374579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: Fluid challenge and measure change in co2 gap
Study NCT00845351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: bexarotene at 300 mg/m2/day
Study NCT02637999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG IFN alfa-2a
Study NCT02637999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Study NCT01922141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
Study NCT01922141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
Study NCT01922141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
Study NCT02042807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02042807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS®
Study NCT03392922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uniblocker
Description: The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
Study NCT03392922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left-sided Double-lumen Tube
Description: the double-lumen tube (DLT) is the most commonly used device for OLV
Study NCT00594334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Weekly Risedronate
Study NCT02381366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Description: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg
Study NCT02088359 — intervention group
Intervention type: OTHER
Intervention: Cycled light
Description: We covered the incubator with blanket for darkness approximately 12 hours.
Study NCT02088359 — intervention group
Intervention type: OTHER
Intervention: Continue near darkness
Description: We covered the incubator with blanket all days.
Study NCT02840019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational MRI coil designed for pregnant women
Description: The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
Study NCT02840019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
Study NCT03001141 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
Study NCT03344458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon hGH
Description: Once weekly subcutaneous injection of TransCon hGH
Study NCT01133600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cubicin
Description: dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is \<30ml/min.
Study NCT01133600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
Study NCT01922141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
Study NCT01922141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
Study NCT01922141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
Study NCT04528719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection
Study NCT04231175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DWI MRI of the pelvis, abdomen and thorax
Description: Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
Study NCT00487253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miltefosine
Description: Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
Study NCT00487253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
Study NCT03292744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: alfacalcidol 0,5 mcg
Study NCT03292744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alfacalcidol
Description: alfacalcidol 0,5 mcg
Study NCT01914289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Study NCT01914289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Study NCT01807234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Study NCT01807234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
Study NCT01807234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one spray in each nostril and placebo one nasal spray.
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 2.5 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 5 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 10 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 20 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 35 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 50 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 0.5 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 1 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 2.5 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 5 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 10 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 20 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 35 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 50 mg
Description: oral tablet
Study NCT01639040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab 300 mg once weekly (QW) for 4 weeks
Study NCT01639040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Placebo (for Dupilumab) once weekly (QW) for 4 weeks
Study NCT01639040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
Study NCT02180282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22-IPL
Description: The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm.
Study NCT01332942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BAY85-3934
Description: Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
Study NCT01332942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study NCT01332942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
Study NCT01332942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study NCT01332942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study NCT01332942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study NCT00981032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit Summary
Description: The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
Study NCT00981032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Sharing Tool
Description: This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
Study NCT03601754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treadmill/Bicycle exercise testing
Description: Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W
Study NCT03504358 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
Study NCT01807234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo one spray in each nostril and placebo one nasal spray.
Study NCT00886210 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra abdominal drain
Description: Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
Study NCT00886210 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LC without drain
Description: Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
Study NCT00245518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT01733550 — intervention group
Intervention type: DEVICE
Intervention: Home iCare (study nurse)
Description: the intraocular pressure is measured by iCare performed by the study nurse
Study NCT01733550 — intervention group
Intervention type: DEVICE
Intervention: goldmann applanation tonometry
Description: the intraocular pressure is measured by goldmann applanation tonometry
Study NCT01733550 — intervention group
Intervention type: DEVICE
Intervention: home iCare (by patient)
Description: the intraocular pressure is measured by the iCare performed by the patient him self
Study NCT00233727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HPV DNA Testing + Cryosurgery
Description: Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women.
Study NCT00233727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VIA + Cryosurgery
Description: Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women.
Study NCT01074229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection
Study NCT01074229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug .5% Ropivacaine
Description: .5% ropivacaine 20 mls on each side of abdomen
Study NCT01074229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 cc of 0.25% ropivacaine
Description: Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
Study NCT03555617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473
Description: oral capsule/tablet, QD
Study NCT03555617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral solution, QD
Study NCT02791685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MULTIFIT Cardiac Rehabilitation
Description: MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
Study NCT02791685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movn Pulmonary Rehabilitation
Description: Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
Study NCT02791685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Cardiac Rehabilitation
Description: Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
Study NCT02197494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 320mg tablets